keyword
MENU ▼
Read by QxMD icon Read
search

Metabolic syndrome antipsychotic

keyword
https://www.readbyqxmd.com/read/28449563/relationship-between-serum-bilirubin-levels-and-metabolic-syndrome-in-patients-with-schizophrenia-spectrum-disorders
#1
Filiz Karadag, Ceyhan Balci Sengul, Yasar Enli, Kamuran Karakulah, Huseyin Alacam, Bunyamin Kaptanoglu, Ozgur Kalkanci, Hasan Herken
Objective: We investigated the relationship between serum bilirubin levels and metabolic syndrome (MetS), and the longitudinal effects of baseline serum bilirubin concentrations on MetS in patients with schizophrenia spectrum disorders undergoing atypical antipsychotics. Methods: The sample of this study consisted of 131 patients with schizophrenia spectrum disorders. Waist circumference, blood pressure, and levels of triglycerides, high-density lipoprotein cholesterol, fasting glucose, and insulin were evaluated at baseline and at month six...
May 31, 2017: Clinical Psychopharmacology and Neuroscience: the Official Scientific Journal of the Korean College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/28449562/longer-telomere-length-of-t-lymphocytes-in-patients-with-early-and-chronic-psychosis
#2
Yin Cui, Vishwanath Vasudev Prabhu, Thong Ba Nguyen, Subramaniam Mohana Devi, Young-Chul Chung
Objective: To investigate pathological conditions that act as sources of pro-inflammatory cytokines and cytotoxic substances to examine telomere length (TL) in patients with either early (duration of illness [DI] ≤5 years) or chronic (DI >5 years) psychosis using T lymphocytes. Methods: Based on these factors and the important role that T lymphocytes play in inflammation, the present study measured the TL of T lymphocytes in patients with either early or chronic psychosis...
May 31, 2017: Clinical Psychopharmacology and Neuroscience: the Official Scientific Journal of the Korean College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/28443526/transformation-of-excess-mortality-in-people-with-schizophrenia-and-bipolar-disorder-in-taiwan
#3
Y-J Pan, L-L Yeh, H-Y Chan, C-K Chang
BACKGROUND: Given the concerns regarding the adverse health outcomes associated with weight gain and metabolic syndrome in relation to use of second-generation antipsychotics (SGAs), we aimed in this study to explore whether the increase in the use of SGAs would have any impacts on the trend of excess mortality in people with schizophrenia and bipolar disorder (BPD). METHOD: Two nationwide samples of individuals with schizophrenia and BPD were identified in Taiwan's National Health Insurance Research Database in 2003 and in 2008, respectively...
April 26, 2017: Psychological Medicine
https://www.readbyqxmd.com/read/28443024/low-dose-of-bergamot-derived-polyphenolic-fraction-bpf-did-not-improve-metabolic-parameters-in-second-generation-antipsychotics-treated-patients-results-from-a-60-days-open-label-study
#4
Antonio Bruno, Gianluca Pandolfo, Manuela Crucitti, Massimo Cacciola, Vincenza Santoro, Edoardo Spina, Rocco A Zoccali, Maria R A Muscatello
Objectives: The nutraceutical approach to the management of metabolic syndrome (MetS) might be a promising strategy in the prevention of cardio-metabolic risk. Low-dose bergamot-derived polyphenolic fraction (BPF) has been proven effective in patients with MetS, as demonstrated by a concomitant improvement in lipemic and glycemic profiles. The present study was aimed to further explore, in a sample of subjects receiving second generation antipsychotics (SGAs), the effects on body weight and metabolic parameters of a low dose of BPF (500 mg/day) administered for 60 days...
2017: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/28437058/psychotic-and-bipolar-disorders-antipsychotic-drugs
#5
Sarah D Holder, Alaina L Edmunds, Sherri Morgan
Antipsychotic drugs block dopamine receptors and are used to manage psychosis as well as other mental illnesses that may or may not have psychotic features, such as bipolar disorders and major depressive disorder. First-generation antipsychotic drugs are more likely to cause adverse effects such as extrapyramidal symptoms and tardive dyskinesia. Adverse effects of second-generation antipsychotic drugs typically are related to metabolic abnormalities such as weight gain, abnormal blood glucose levels, and elevated lipid levels...
April 2017: FP Essentials
https://www.readbyqxmd.com/read/28412910/aripiprazole-a-drug-that-displays-partial-agonism-and-functional-selectivity
#6
Erin W Tuplin, Matthew R Holahan
The treatment of schizophrenia is challenging due to the wide range of symptoms (positive, negative, cognitive) associated with the disease. Typical antipsychotics that antagonize D2 receptors are effective in treating positive symptoms, but extrapyramidal side-effects (EPS) are a common occurrence. Atypical antipsychotics targeting 5-TH2A and D2 receptors are more effective at treating cognitive and negative symptoms compared to typical antipsychotics, but these drugs also result in side-effects such as metabolic syndromes...
April 13, 2017: Current Neuropharmacology
https://www.readbyqxmd.com/read/28406267/long-term-antipsychotic-use-and-major-cardiovascular-events-a-retrospective-cohort-study
#7
Alejandro G Szmulewicz, Federico Angriman, Felipe E Pedroso, Carolina Vazquez, Diego J Martino
OBJECTIVE: Chronic treatment with antipsychotics may result in both metabolic side effects and cardiovascular disease. Our aim was to evaluate the effect of antipsychotic medications categorized by their metabolic side effect profiles as low, intermediate, or high risk on major cardiovascular events. METHODS: A retrospective cohort study was conducted in adult outpatients aged 30 years or older initiating antipsychotic treatment from 2002 to 2007. Antipsychotic medications were divided into 3 groups (low-, intermediate-, and high-risk) according to the severity of their side-effect profiles in developing metabolic abnormalities associated with cardiovascular disease...
April 11, 2017: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/28402033/metabolic-syndrome-in-antipsychotic-naive-african-patients-with-severe-mental-illness-in-usual-care
#8
Shamima Saloojee, Jonathan K Burns, Ayesha A Motala
BACKGROUND: To determine the prevalence and incidence of metabolic syndrome in individuals with a first episode of severe mental illness from South Africa. METHODS: Antipsychotic naïve study subjects with a first episode of severe mental illness and control subjects were recruited at baseline for a prospective study. Individuals without metabolic syndrome at baseline were followed up for 12 months after antipsychotic medication was initiated. Metabolic syndrome was determined at baseline and at the 12-month follow-up using the Joint Interim Statement criteria...
April 12, 2017: Early Intervention in Psychiatry
https://www.readbyqxmd.com/read/28370308/prescribing-in-schizophrenia-and-psychosis-increasing-polypharmacy-over-time
#9
Adrian Heald, Mark Livingston, Alison Yung, M A De Hert
INTRODUCTION: Diabetes, obesity, and metabolic syndrome are highly prevalent in patients with severe mental illness. Psychotropic polypharmacy is becoming increasingly prevalent within the UK. We determined the change in the number of psychotropic medications prescribed over time and trends in weight and fasting blood glucose. METHODS: One hundred ninety-five individuals with schizophrenia and psychosis on the Severe Mental Illness Register in Cheshire, UK, were followed up between 2004 and 2012...
March 2017: Human Psychopharmacology
https://www.readbyqxmd.com/read/28366084/metabolic-syndrome-prevalence-and-reduction-in-inmates-prescribed-antipsychotic-medications
#10
Rusty Reeves, Anthony Tamburello, Lisa DeBilio
The principal aim of this study was to establish whether a metabolic monitoring program implemented for second-generation antipsychotic medications (SGAs) was associated with any reduction in the prevalence of metabolic syndrome in adult inmates treated with antipsychotic medications in the New Jersey Department of Corrections. The average prevalence of metabolic syndrome in those prescribed SGAs decreased from 17.9% during the years before metabolic monitoring to 14.3% during the years of monitoring. The number of patients prescribed antipsychotic medication decreased a net 35% over 9 years of the study...
January 1, 2017: Journal of Correctional Health Care
https://www.readbyqxmd.com/read/28350151/-the-relationship-between-posttraumatic-stress-disorder-and-metabolic-syndrome-an-overview
#11
S M Dieleman, J P de Jong
BACKGROUND: In this article we discuss the relationship between posttraumatic stress disorder (PTSD) and metabolic syndrome (MbS). AIM: To assess the prevalence of MbS in patients with PTSD, establish which factors are involved and to consider what the implications are for clinical practice. METHOD: We performed a systematic search of the literature, using Medline, Embase Psychiatry and PsycINFO covering the period January 1990 up to and including October 2014...
2017: Tijdschrift Voor Psychiatrie
https://www.readbyqxmd.com/read/28344764/atypical-antipsychotics-recent-research-findings-and-applications-to-clinical-practice-proceedings-of-a-symposium-presented-at-the-29th-annual-european-college-of-neuropsychopharmacology-congress-19-september-2016-vienna-austria
#12
REVIEW
Robin Murray, Christoph U Correll, Gavin P Reynolds, David Taylor
Available evidence suggests that second-generation atypical antipsychotics are broadly similar to first-generation agents in terms of their efficacy, but may have a more favourable tolerability profile, primarily by being less likely to cause extrapyramidal symptoms. However, atypical antipsychotics are variably associated with disturbances in the cardiometabolic arena, including increased body weight and the development of metabolic syndrome, which may reflect differences in their receptor binding profiles...
March 2017: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/28338545/risperidone-and-cardiometabolic-risk-in-children-and-adolescents-clinical-and-instrumental-issues
#13
Emilia Matera, Lucia Margari, Vincenzo Ostilio Palmieri, Giuseppina Zagaria, Roberto Palumbi, Francesco Margari
PURPOSE/BACKGROUND: Although second-generation antipsychotics are used to treat and manage symptoms for several psychiatric disorders, data about their adverse effects in developmental age are limited. The aim of this prospective observational study was to verify the cardiovascular and metabolic risk in a sample of antipsychotic-naive children/adolescent patients starting risperidone therapy. METHODS: Twenty-two patients, younger than 18 years, were recruited. The assessment included anthropometric data, cardiovascular parameters, blood tests, and ultrasonographic abdominal study...
June 2017: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28335658/dopamine-antagonists-for-treatment-resistance-in-autism-spectrum-disorders-review-and-focus-on-bdnf-stimulators-loxapine-and-amitriptyline
#14
REVIEW
Jessica A Hellings, L Eugene Arnold, Joan C Han
Drug development and repurposing are urgently needed for individuals with autism spectrum disorders (ASD) and psychiatric comorbidity, which often presents as aggression and self-injury. Areas covered: We review dopamine antagonists, including classical and atypical, as well as unconventional antipsychotics in ASD. The older antipsychotic loxapine is discussed in terms of preliminary albeit limited evidence in ASD. Emerging promise of amitriptyline in ASD is discussed, together with promising BDNF effects of loxapine and amitriptyline...
April 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28296430/successful-use-of-sertindole-for-severe-behavioral-dyscontrol-in-a-pediatric-case-of-syndromic-autism-spectrum-disorder
#15
Ahmed Naguy
Autism spectrum disorder (ASD) is commonly associated with a host of challenging behaviors. Pharmacotherapy is indicated if psychosocial and educational interventions fail. Atypical antipsychotics have the strongest evidence base so far, with both risperidone and aripiprazole being FDA approved. Unfortunately, their use is fraught with metabolic and neurohormonal side effects. In this study, the author is reporting on a case of syndromic ASD/moderate intellectual disability with severe behavioral component that failed multiple psychotropic trials and ultimately responded dramatically to sertindole...
March 15, 2017: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/28260235/no-cognitive-enhancing-effect-of-glp-1-receptor-agonism-in-antipsychotic-treated-obese-patients-with-schizophrenia
#16
P L Ishøy, B Fagerlund, B V Broberg, N Bak, F K Knop, B Y Glenthøj, B H Ebdrup
OBJECTIVE: Schizophrenia is associated with profound cognitive and psychosocial impairments. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are used for diabetes and obesity treatment, and animal studies have indicated cognitive-enhancing effects. In this investigator-initiated, double-blind, randomized, placebo-controlled trial, we tested non-metabolic effects of exenatide once-weekly (Bydureon™) in obese, antipsychotic-treated patients with schizohrenia spectrum disorder. METHOD: Before and after 3 months of exenatide (N = 20) or placebo (N = 20) treatment, patients were assessed with the following: Brief Assessment of Cognition in Schizophrenia (BACS), Rey-Osterreith complex figure test (REY), Short-Form Health Survey (SF-36), Personal and Social Performance Scale (PSP) and the Positive and Negative Syndrome Scale (PANSS)...
March 5, 2017: Acta Psychiatrica Scandinavica
https://www.readbyqxmd.com/read/28226264/leukocyte-telomere-length-in-hispanic-schizophrenia-patients-under-treatment-with-olanzapine
#17
Nancy Monroy-Jaramillo, Yaneth Rodríguez-Agudelo, Luis Carlos Aviña-Cervantes, David L Roberts, Dawn I Velligan, Consuelo Walss-Bass
Different lines of evidence indicate that patients with schizophrenia (SZ) exhibit accelerated aging. Leukocyte telomere length (TL), an aging marker, is associated with age-related and chronic pathologies, including schizophrenia. We analyzed leukocyte TL in 170 SZ patients of Hispanic ancestry grouped based on antipsychotic treatment, compared to 126 matched controls. The group under treatment with atypical antipsychotics was further subdivided according to the risk of medication to cause metabolic syndrome (MetS)...
February 10, 2017: Journal of Psychiatric Research
https://www.readbyqxmd.com/read/28214752/metabolic-syndrome-and-cardiovascular-risk-among-institutionalized-patients-with-schizophrenia-receiving-long-term-tertiary-care
#18
Lee Seng Esmond Seow, Siow Ann Chong, Peizhi Wang, Saleha Shafie, Hui Lin Ong, Mythily Subramaniam
BACKGROUND: Metabolic syndrome (MetS) and cardiovascular risk are highly prevalent among individuals with schizophrenia. This study aimed to determine the cardiometabolic profile and the associated risk factors in a group of institutionalized patients with schizophrenia or schizoaffective disorder receiving prolonged hospital care in the only tertiary psychiatric institution in Singapore. METHODS: Patients residing in long stay wards who were hospitalized for a minimum period of 1year were recruited...
February 2, 2017: Comprehensive Psychiatry
https://www.readbyqxmd.com/read/28209485/effects-of-clozapine-on-adipokine-secretions-productions-and-lipid-droplets-in-3t3-l1-adipocytes
#19
Tomomi Tsubai, Akira Yoshimi, Yoji Hamada, Makoto Nakao, Hiroshi Arima, Yutaka Oiso, Yukihiro Noda
Clozapine, a second-generation antipsychotic (SGA), is a cause of side effects related to metabolic syndrome. The participation of serotonin 5-HT2C and histamine H1 receptors in the central nervous system has been reported as a mechanism of the weight gain caused by clozapine. In the present study, we investigated the direct pharmacological action of clozapine on the 3T3-L1 adipocytes and compared it to that of blonanserin, an SGA with low affinity for both receptors. Short-term exposure to clozapine decreased secretion and mRNA expression of leptin...
January 28, 2017: Journal of Pharmacological Sciences
https://www.readbyqxmd.com/read/28196698/-when-and-how-prescribe-antipsychotics
#20
S Tebeka, G Airagnes, F Limosin
Antipsychotics are commonly prescribed in the general population since they have many indications. They can be used in acute care such as agitation or behavior disorders, or to treat more characterized psychiatric disorders like psychotic or mood disorders. Consequently, any practitioner will have to prescribe or renew a prescription of antipsychotics. These treatments require a benefit/risk balance assessment taking into account the specific context of each patient. Indeed, antipsychotics have many side effects, mainly neurological (extrapyramidal syndrome, dyskinesia, akathisia), metabolic and cardiac...
May 2017: La Revue de Médecine Interne
keyword
keyword
73394
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"